9.99 USD
▼-0.44-4.22%
盘后 9.70 -2.90%
2026-09-15
市值
$340.06M
市盈率
—
EPS
-4.15
股息率
—
52 周区间
9.80 – 33.20
成交量
520.00K
Beta
—
目标价
24.13
52W 低 9.8052W 高 33.20
价格走势
公司简介
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
关联新闻
- Evommune scraps eczema drug after trial miss, shares plunge
Evommune said on Tuesday it will not advance its experimental skin disease drug after it failed to meet the main goal in a mid-stage trial, sending its shares down 24% in aftermarket trading.